nach oben

High Blood Pressure & Cardiovascular Prevention

Erschienen in:

07.06.2023 | Review article

Plasma Lipoprotein(a) Levels in Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

verfasst von: Walter Masson, Leandro Barbagelata, Martín Lobo, Augusto Lavalle-Cobo, Pablo Corral, Juan Patricio Nogueira

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The polycystic ovary syndrome (PCOS) may represent an important model of lipid alterations. Lipoprotein(a) [Lp(a)] has emerged as a new marker of cardiovascular risk.

Aim

The main objective of this meta-analysis was to analyze the available evidence on Lp(a) levels in patients with PCOS compared to a control group.

Methods

This meta-analysis was performed according to PRISMA guidelines. A literature search was performed to detect studies that have quantified Lp(a) levels in women with PCOS compared to a control group. The primary outcome was Lp(a) levels expressed in mg/dL. Random effects models were used.

Results

Twenty-three observational studies including 2,337 patients were identified and considered eligible for this meta-analysis. In the overall analysis, the quantitative analysis showed that patients with PCOS have a higher Lp(a) levels (SMD: 1.1 [95% CI: 0.7 to 1.4]; I²=93%) compared to the control group. The results were similar in the analysis of the subgroups of patients according to body mass index (normal weight group: SMD: 1.2 [95% CI: 0.5 to 1.9], I²=95%; overweight group: SMD: 1.2 [95% CI: 0.5 to 1.8], I²=89%). Sensitivity analysis showed that the results were robust.

Conclusions

This meta-analysis shows that women with PCOS had higher levels of Lp(a) compared to healthy women used as a control group. These findings were observed in both overweight and non-overweight women.

Liu J, Wu Q, Hao Y, Jiao M, Wang X, Jiang S, Han L. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. Hum Reprod. 2021;36:1108–19.CrossRefPubMedPubMedCentral

El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly cystic ovarian syndrome: an updated overview. Front Physiol. 2016;5(7):124. https://doi.org/10.3389/fphys.2016.00124.CrossRef

Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, Kumar M. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023;12(4):1454. https://doi.org/10.3390/jcm12041454.CrossRefPubMedPubMedCentral

Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011;95(3):1073-9.e1-11. https://doi.org/10.1016/j.fertnstert.2010.12.027.CrossRefPubMed

Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–46. https://doi.org/10.1093/eurheartj/ehac361.CrossRefPubMedPubMedCentral

Bhatia HS, Wilkinson MJ. Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies. J Clin Med. 2022;11(20):6040. https://doi.org/10.3390/jcm11206040.CrossRefPubMedPubMedCentral

Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 1997;46(4):454–7. https://doi.org/10.1016/s0026-0495(97)90066-4.CrossRefPubMed

Dejager S, Pichard C, Giral P, Bruckert E, Federspield MC, Beucler I, Turpin G. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf). 2001;54(4):455–62. https://doi.org/10.1046/j.1365-2265.2001.01245.x.CrossRefPubMed

Yildiz BO, Haznedaroğlu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002;87(8):3871–5. https://doi.org/10.1210/jcem.87.8.8716.CrossRefPubMed

10.

Yilmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Törüner F, Paşaoğlu H. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol. 2005;20(5):258–63. https://doi.org/10.1080/09513590400027265.CrossRefPubMed

11.

Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Cakir N, Arslan M. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005;20(12):3333–40. https://doi.org/10.1093/humrep/dei258.CrossRefPubMed

12.

Bickerton AST, Clark N, Meeking D, Shaw KM, Crook M, Lumb P, Turner C, Cummings MH. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol. 2005;58(2):151–4. https://doi.org/10.1136/jcp.2003.015271.CrossRefPubMedPubMedCentral

13.

Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, Petakov M, Rousso D, Kourtis A, Bjekic J, Milic N. Oxidised low-density lipoprotein concentration—early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol. 2006;155(1):131–6. https://doi.org/10.1530/eje.1.02187.CrossRefPubMed

14.

Hu WH, Qiao J, Zhao SY, Zhang XW, Li MZ. Monocyte chemoattractant protein-1 and its correlation with lipoprotein in polycystic ovary syndrome. Beijing Da Xue Xue Bao Yi Xue Ban. 2006;38(5):487–91.PubMed

15.

Yilmaz S, Kursad U, Ayse Y, Ali Y, Ercan A, Fahrettin K. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2007;67(6):904–8. https://doi.org/10.1111/j.1365-2265.2007.02985.x.CrossRef

16.

Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, Carmina E. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. Int J Clin Pract. 2009;63(1):56–62. https://doi.org/10.1111/j.1742-1241.2008.01897.x.CrossRefPubMed

17.

Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod. 2009;24(9):2286–92. https://doi.org/10.1093/humrep/dep121.CrossRefPubMed

18.

Yilmaz M, Bukan N, Demirci H, Oztürk C, Kan E, Ayvaz G, Arslan M. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25(4):246–52. https://doi.org/10.1080/09513590802653833.CrossRefPubMed

19.

Arikan S, Bahceci M, Tuzcu A, Kale E, Gökalp D. Serum resistin and adiponectin levels in young non-obese women with polycystic ovary syndrome. Gynecol Endocrinol. 2010;26(3):161–6. https://doi.org/10.3109/09513590903247816.CrossRefPubMed

20.

Güdücü N, İşçi H, Görmüş U, Yiğiter AB, Dünder I. Serum visfatin levels in women with polycystic ovary syndrome. Gynecol Endocrinol. 2012;28(8):619–23. https://doi.org/10.3109/09513590.2011.650749.CrossRefPubMed

21.

Güdücü N, Işçi H, Yiğiter AB, Dünder I. C-reactive protein and lipoprotein-a as markers of coronary heart disease in polycystic ovary syndrome. J Turk Ger Gynecol Assoc. 2012;13(4):227–32. https://doi.org/10.5152/jtgga.2012.35.CrossRefPubMedPubMedCentral

22.

Kim JJ, Chae SJ, Choi YM, Hwang KR, Song SH, Yoon SH, Kim SM, Ku SY, Kim SH, Kim JG, Moon SY. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome. Hum Reprod. 2013;28(5):1354–60. https://doi.org/10.1093/humrep/det057.CrossRefPubMed

23.

Tsouma I, Kouskouni E, Gennimata V, Demeridou S, Boutsikou M, Grigoriou V, Chasiakou A, Hassiakou S, Baka S. Leptin levels in women with polycystic ovaries undergoing ovarian stimulation: relation to lipoprotein profiles. In Vivo. 2014;28(5):989–92.PubMed

24.

Tsouma I, Kouskouni E, Demeridou S, Boutsikou M, Hassiakos D, Chasiakou A, Hassiakou S, Gennimata V, Baka S. Lipid lipoprotein profile alterations in Greek infertile women with polycystic ovaries: influence of adipocytokines levels. In Vivo. 2014;28(5):935–9.PubMed

25.

Kumar PS, Ananthanarayanan PH, Rajendiran S. Cardiovascular risk markers and thyroid status in young Indian women with polycystic ovarian syndrome: a case-control study. J Obstet Gynaecol Res. 2014;40(5):1361–7. https://doi.org/10.1111/jog.12346.CrossRef

26.

Tsouma I, Kouskouni E, Demeridou S, Boutsikou M, Hassiakos D, Chasiakou A, Hassiakou S, Baka S. Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation. Gynecol Endocrinol. 2014;30(7):516–9. https://doi.org/10.3109/09513590.2014.896896.CrossRefPubMed

27.

Tu AS, Zhong Y, Mao XG. Changes of serum TOS and TAS levels and their association with apolipoprotein(a) in patients with polycystic ovary syndrome and infertility. Nan Fang Yi Ke Da Xue Xue Bao. 2016;36(3):405–9.PubMed

28.

Bousmpoula A, Kouskouni E, Benidis E, Demeridou S, Kapeta-Kourkouli R, Chasiakou A, Baka S. Adropin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with lipoprotein lipid profiles. Gynecol Endocrinol. 2018;34(2):153–6. https://doi.org/10.1080/09513590.2017.1379498.CrossRefPubMed

29.

Shah AK, Yadav BK, Suri A, Shah AK. A study on lipoprotein-a and PAI-1 in women with polycystic ovary syndrome. Horm Mol Biol Clin Investig. 2022;43(3):357–61. https://doi.org/10.1515/hmbci-2021-0044.CrossRefPubMed

30.

Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, Pavlaki A, Stergianos S, Poulasouchidou M, Tzellos TG, Makedos A, Chourdakis M, Tarlatzis BC. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 2011;17(6):741–60. https://doi.org/10.1093/humupd/dmr025.CrossRefPubMed

31.

Arya S, Kaji AH, Boermeester MA. PRISMA reporting guidelines for meta-analyses and systematic reviews. JAMA Surg. 2021;156(8):789–90. https://doi.org/10.1001/jamasurg.2021.0546.CrossRefPubMed

32.

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins J. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.CrossRefPubMedPubMedCentral

33.

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.CrossRefPubMedPubMedCentral

34.

Viechtbauer W. Conducting meta-analyses in R with the metaphor package. J Stat Softw. 2010;36:1–48.CrossRef

35.

Pustejovsky JE, Rodgers MA. Testing for funnel plot asymmetry of standardized mean differences. Res Synth Methods. 2019;10(1):57–71. https://doi.org/10.1002/jrsm.1332.CrossRefPubMed

36.

Shrivastava S, Conigliaro RL. Polycystic ovarian syndrome. Med Clin N Am. 2023;107(2):227–34. https://doi.org/10.1016/j.mcna.2022.10.004.CrossRefPubMed

37.

Berni TR, Morgan CL, Rees DA. Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: a population study. J Clin Endocrinol Metab. 2021;106(9):e3369–80. https://doi.org/10.1210/clinem/dgab392.CrossRefPubMedPubMedCentral

38.

Anagnostis P, Paparodis RD, Bosdou JK, Bothou C, Macut D, Goulis DG, Livadas S. Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies. Endocrine. 2021;74(2):245–53. https://doi.org/10.1007/s12020-021-02801-2.CrossRefPubMed

39.

Tehrani FR, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2020;36(1):12–23. https://doi.org/10.1080/09513590.2019.1650337.CrossRef

40.

Vekic J, Zeljkovic A, Al Rasadi K, Cesur M, Silva Nunes J, Stoian AP, Rizzo M. A new look at novel cardiovascular risk biomarkers: the role of atherogenic lipoproteins and innovative antidiabetic therapies. Metabolites. 2022;12(2):108. https://doi.org/10.3390/metabo12020108.CrossRefPubMedPubMedCentral

41.

Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013;273(1):6–30. https://doi.org/10.1111/j.1365-2796.2012.02592.x.CrossRefPubMed

42.

Tatsumi Y, Nakao YM, Masuda I, Higashiyama A, Takegami M, Nishimura K, Watanabe M, Ohkubo T, Okamura T, Miyamoto Y. Risk for metabolic diseases in normal weight individuals with visceral fat accumulation: a cross-sectional study in Japan. BMJ Open. 2017;7(1):e013831. https://doi.org/10.1136/bmjopen-2016-013831.CrossRefPubMedPubMedCentral

43.

Gaeta G, Lanero S, Barra S, Silvestri N, Cuomo V, Materazzi C, Vitagliano G. Sex hormones and lipoprotein(a) concentration. Expert Opin Investig Drugs. 2011;20(2):221–38. https://doi.org/10.1517/13543784.2011.548804.CrossRefPubMed

44.

Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022;349:53–62. https://doi.org/10.1016/j.atherosclerosis.2022.04.006.CrossRefPubMedPubMedCentral

45.

Guzik TJ, Skiba DS, Touyz RM, Harrison DG. The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovasc Res. 2017;113:1009–23. https://doi.org/10.1093/cvr/cvx108.CrossRefPubMedPubMedCentral

46.

Inal HA, Yilmaz N, Gorkem U, Oruc AS, Timur H. The impact of follicular fluid adiponectin and ghrelin levels based on BMI on IVF outcomes in PCOS. J Endocrinol Invest. 2016;39(4):431–7. https://doi.org/10.1007/s40618-015-0392-6.CrossRefPubMed

47.

Guler E, Guler GB, Kizilirmak F, Batgerel U, Demir GG, Gunes HM, Özcan Ö, Barutcu I, Turkmen MM, Esen AM. Evaluation of adiponectin and lipoprotein(a) levels in cardiac syndrome X. Herz. 2015;40(Suppl 3):291–7. https://doi.org/10.1007/s00059-014-4191-1.CrossRefPubMed

48.

Simantiris S, Antonopoulos AS, Papastamos C, Benetos G, Koumallos N, Tsioufis K, Tousoulis D. Lipoprotein(a) and inflammation- pathophysiological links and clinical implications for cardiovascular disease. J Clin Lipidol. 2023;17(1):55–63. https://doi.org/10.1016/j.jacl.2022.10.004.CrossRefPubMed

49.

Gleicher N, Darmon S, Patrizio P, Barad DH. Reconsidering the polycystic ovary syndrome (PCOS). Biomedicines. 2022;10(7):1505. https://doi.org/10.3390/biomedicines10071505.CrossRefPubMedPubMedCentral

50.

Bjornstad P, Eckel RH. Pathogenesis of lipid disorders in insulin resistance: a brief review. Curr Diab Rep. 2018;18(12):127. https://doi.org/10.1007/s11892-018-1101-6.CrossRefPubMedPubMedCentral

51.

Cardoso-Saldaña GC, González-Salazar MDC, Posadas-Sánchez R, Vargas-Alarcón G. Metabolic syndrome, lipoprotein(a) and subclinical atherosclerosis in Mexican population. Arch Cardiol Mex. 2021;91(3):307–14. https://doi.org/10.24875/ACM.20000276.CrossRefPubMed

52.

Bozbas H, Yildirir A, Pirat B, Eroğlu S, Korkmaz ME, Atar I, Ulus T, Aydinalp A, Ozin B, Müderrisoğlu H. Increased lipoprotein(a) in metabolic syndrome: is it a contributing factor to premature atherosclerosis? Anadolu Kardiyol Derg. 2008;8:111–5.PubMed

53.

Wu XY, Lin L, Qi HY, Du R, Hu CY, Ma LN, Peng K, Li M, Xu Y, Xu M, Chen YH, Lu JL, Bi YF, Wang WQ, Ning G. Association between lipoprotein(a) levels and metabolic syndrome in a middle-aged and elderly Chinese cohort. Biomed Environ Sci. 2019;32(7):477–85. https://doi.org/10.3967/bes2019.065.CrossRefPubMed

Titel: Plasma Lipoprotein(a) Levels in Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis
verfasst von: Walter Masson
Leandro Barbagelata
Martín Lobo
Augusto Lavalle-Cobo
Pablo Corral
Juan Patricio Nogueira
Publikationsdatum: 07.06.2023
Verlag: Springer International Publishing
Erschienen in: High Blood Pressure & Cardiovascular Prevention / Ausgabe 4/2023
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI: https://doi.org/10.1007/s40292-023-00585-2

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Plasma Lipoprotein(a) Levels in Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

Abstract

Introduction

Aim

Methods

Results

Conclusions

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction

Aim

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Pre-stroke Adherence to Hypertension Medications in a Bi-racial United States Stroke Belt

A Systematic Review and Meta-analysis of the Clinical and Epidemiological Characteristics of Patients with Hypertensive Emergencies: Implication for Risk Stratification

Impacts of Anxiety and Depression on Clinical Hypertension in Low-Income US Adults

A Randomized Controlled Trial of Blood Pressure Reduction Based on Disease Control Priorities 3 in Pakistan to Manage and Control Hypertension

Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview

Low Potassium Intake: A Common Risk Factor for Nephrolithiasis in Patients with High Blood Pressure

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie